MedTrace Logo

A Phase II Study Investigating Upfront Pazopanib In Metastatic Renal Cancer Renal Cancer (Panther)

NCT01512186 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 95

Last updated 2014-06-12

No results posted yet for this study

Summary

The purpose of this study is to investigate if 14 weeks of pazopanib therapy prior to surgery (nephrectomy) is of benefit to patients with metastatic renal cancer. Ninety-five patients will be recruited into his study.

Conditions

  • Metastatic Clear Cell Renal Cancer

Sponsors & Collaborators

  • Queen Mary University of London

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2014-02-28
Completion
2014-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01512186 on ClinicalTrials.gov